FDA wants to hear from you!

FDAThere’s still time and opportunity to tell the FDA your thoughts on drug development for Huntington disease!

The FDA focused on hearing from individuals with HD, family members and caregivers at its Sept. 22 Patient Focused Drug Development hearing. But from now until Nov. 23, the FDA is taking input from the entire HD community, including care providers and researchers. Specifically the FDA wants to know: At all stages of HD/JHD, if a treatment could be developed, what symptom would you most like to stop or what ability would you like to regain – what is most important to you?

The other topics about which the FDA is gathering input include the symptoms that affect daily life, how the disease affects social interactions and relationships, and how treatments have changed over time. To see the full list of topics, click here.

This is your chance to advocate on behalf of HD families and underscore with our country’s drug development process how imperative it is to address the many symptoms of HD. Please take advantage of this opportunity.

To submit your comments, click here and then click on the green “Submit a Formal Comment” button on the right side of the screen.


CLOSED: Call for Abstracts: 9th Annual HD Clinical Research Symposium

CLOSED: Call for Abstracts

9th Annual HD Clinical Research Symposium: Saturday, October 24, 2015

Deadline for Receipt of Abstracts: July 13, 2015

Late Breaking Research Deadline: August 17, 2015

The Huntington Study Group (HSG) is organizing the Ninth Annual Huntington Disease Clinical Research Symposium (HDCRS) on Saturday, October 24, 2015 at the Grand Hyatt Tampa Bay in Tampa, Florida. In recognition of the focus on patient-oriented research, the HSG convened the first annual Clinical Research Symposium in 2007 to present valuable research and information to both clinicians and HD patients and family members.

Eligible abstracts may include data that have been presented previously, but please ensure they will still be of public, as well as scientific, interest. Authors will be asked to disclose relationships with funding sources and manufacturers of commercial products discussed in the presentation. The Symposium Committee will review and accept a limited number of abstracts for either platform or poster presentations. Accepted abstracts will be published in the journal Neurotherapeutics, and the primary presenting author will receive a night of lodging at the Grand Hyatt Tampa Bay. There is no registration fee to attend the HDCRS if attendees pre-register by October 16, 2015.

Deadline for receipt of abstracts is Monday, July 13, 2015 by 5:00PM, ET.

Late-Breaking Research Abstracts: Authors whose research data were not available until after the regular abstract deadline of July 13, 2015 are invited to submit a late-breaking abstract. Such late-breaking research submissions should represent original work not previously published.

Late-breaking research abstracts must be submitted by Monday, August 17, 2015 by 5:00PM, ET and should include an explanation of why this abstract was not submitted by the July 13th deadline.

Deadline for receipt of abstract is July, 13 2015 by 5pm, ET


Apply to be a Shoulson Scholar

Shoulson Scholar Award

In honor of our founder, Dr. Ira Shoulson, the HSG has established the ‘Shoulson Scholar Fund.’ This fund will recognize outstanding junior investigators with a future of promising research in Huntington disease. The Shoulson Scholar Fund will be awarded to recipients in support of attendance of HSG 2015, the HSG’s annual meeting in Tampa, Florida, October 21-24, 2015. The award will support travel (airfare), 2 nights lodging, a travel stipend, and a $250 honorarium.


Applicants will be asked to submit a CV or Biosketch, a letter of interest (under 150 words), and a scientific abstract for the HD Clinical Research Symposium. These applications will be reviewed by an HSG Committee. The recipients will be expected to go through the approved HSG vendors in order to arrange travel and attendance at the meeting, and are also expected to attend the meeting.

Application DEADLINE: Monday, August 17, 2015

Applicants can submit their interest via our online application.

Scholars will be recognized formally at the meeting via award and speaker presentations. Abstracts accepted for the Symposium will be published inNeurotherapeutics and scholars will be asked to present their abstract to the Symposium audience during poster sessions.* Recognition of the funders for this scholarship program will be appropriately recognized.

*Note that all submitted abstracts will be considered for these opportunities, regardless of Shoulson Scholarship reception. All primary authors on accepted abstracts for the Symposium will be provided one night’s lodging at the meeting hotel as well.

Shoulson Scholar Application DEADLINE: Monday, August 17, 2015

1 3 4 5